PRODUCT MONOGRAPH

SEROPHENE®

Clomiphene Citrate Tablets, USP 50 mg

OVULATORY AGENT

EMD Serono, A Division of EMD Inc., Canada
2695 North Sheridan Way, Suite 200
Mississauga, Ontario L5K 2N6
Canada

Date of Revision: December 20, 2016
Submission Control No.: 189606
Registered trademark of Ares Trading S.A.
NAME OF DRUG

SEROPHENE®

Clomiphene Citrate Tablets, USP 50 mg

PHARMACOLOGIC CLASSIFICATION

Ovulatory Agent

ACTIONS

Serophene (clomiphene citrate) is an orally-administered, non-steroidal agent which may induce ovulation in anovulatory women in appropriately selected cases\textsuperscript{1-24}.

Mechanism of Action

The stimulation of an ovulatory response to cyclic SEROPHENE therapy is believed to be related to its antiestrogenic properties; by competing with estrogen for binding sites at the hypothalamic level, it may cause increased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), with subsequent ovarian stimulation and preovulatory LH surge, resulting in maturation of the ovarian follicle and development of the corpus luteum. The involvement of the pituitary is indicated by increased pituitary secretion of gonadotropins and by the response of the ovary as manifested by increased ovarian secretion of estrogen. Following therapy with SEROPHENE, presumptive signs of ovulation resemble those associated with normal menstrual cycle. It should be noted, however, that during drug administration and for several days thereafter, the effects of endogenous estrogen on the vaginal mucosa and cervical mucus are inhibited\textsuperscript{25}.

Suggested criteria for ovulation following SEROPHENE may include the ovulatory peak of estrogen secretion, a biphasic basal body temperature curve, ovarian secretion of progesterone at postovulatory of higher levels, and endometrial histologic findings characteristic of the luteal phase. In most patients, ovulation appears to occur from 6 to 12 days after completion of therapy at recommended dosage. A review of fourteen publications appearing between 1964 and 1983 showed that an ovulatory response occurred in 74\% of 8,228 patients with ovulatory dysfunction who received clomiphene citrate. Successful therapy characterized by pregnancy occurred in 31\% of the 8,228 patients\textsuperscript{1,25-27}.

Pregnancies following clomiphene citrate USP*.
### INDICATIONS

SEROPHENE (clomiphene citrate) is indicated in the treatment of ovulatory failure in patients desiring pregnancy, whose partners have adequate sperm and who have potentially functional hypothalamic-hypophyseal ovarian systems and adequate endogenous estrogens. Impediments to this goal must be excluded or adequately treated before beginning therapy. The workup and treatment of candidates for SEROPHENE therapy should be supervised by physicians experienced in management of gynecologic or endocrine disorders. The workup of the patient must begin with a careful and detailed history of menstrual and reproductive function, and a complete physical examination. It should be followed by a selective and careful laboratory investigation, based on historical and physical findings.

The following considerations are appropriate for selection of patients:

1. If any doubt exists as to the presence of early pregnancy, SEROPHENE therapy should be withheld until a diagnosis of pregnancy has been excluded.

2. The partner’s potential fertility and potency should be ascertained by semen analysis and other indicated examinations.

3. Mechanical impediments to conception, such as tubal obstruction, should be excluded or adequately treated before undertaking SEROPHENE therapy.

4. The diagnosis of ovulatory dysfunction should be established by such standard techniques as basal body temperature curves, serial vaginal smears, cervical mucus, endometrial biopsy and progesterone determination.

5. Appropriate diagnostic measures should be undertaken to exclude primary pituitary failure or primary ovarian failure. Intact pituitary and ovaries are required for successful therapy. Ovulatory dysfunction in the presence of abnormally high levels of pituitary gonadotropins is indicative of ovarian failure, and patients in this category cannot be expected to respond to SEROPHENE. Adequacy of endogenous estrogen, as estimated

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Pregnancy Rate</th>
<th>Ovulation Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarke (1971)</td>
<td>30</td>
<td>70.0</td>
<td>27.0</td>
</tr>
<tr>
<td>O’Herliity et al. (1981)</td>
<td>30</td>
<td>70.0</td>
<td>27.0</td>
</tr>
<tr>
<td>Pildes (1965)</td>
<td>36</td>
<td>50.0</td>
<td>11.1</td>
</tr>
<tr>
<td>Rabau et al. (1967)</td>
<td>101</td>
<td>62.6</td>
<td>33.6</td>
</tr>
<tr>
<td>Rust et al. (1974)</td>
<td>105</td>
<td>91.4</td>
<td>38.1</td>
</tr>
<tr>
<td>Seegar-Jones &amp; Moraes-Ruehsen (1967)</td>
<td>73</td>
<td>83.0</td>
<td>30.1</td>
</tr>
<tr>
<td>Spellacy &amp; Cohen (1967)</td>
<td>35</td>
<td>80.0</td>
<td>20.0</td>
</tr>
<tr>
<td>Sutaria et al. (1980)</td>
<td>51</td>
<td>64.7</td>
<td>31.4</td>
</tr>
<tr>
<td>Whitelow et al. (1964)</td>
<td>37</td>
<td>72.9</td>
<td>45.9</td>
</tr>
<tr>
<td>TOTAL</td>
<td>8,828</td>
<td>74.21</td>
<td>31.33</td>
</tr>
</tbody>
</table>

* The reported data included patients receiving other than recommended dosage regimen.
by vaginal smears, cervical mucus, endometrial biopsy, or blood level of estrogen, furnishes a measure of ovarian function and indirectly of pituitary function. Bleeding after progesterone administration (progesterone alone, not combined with estrogen) furnishes evidence of an adequate level of endogenous estrogen. A good level of endogenous estrogen provides a favourable prognosis for treatment with SEROPHENE. A reduced estrogen level, although less favourable, does not always preclude successful therapy.

6. Patients with abnormal or excessive bleeding should have particularly careful evaluation prior to SEROPHENE therapy. It is most important to ensure that neoplastic lesions are not overlooked.

7. Clinical evaluation of liver function should always precede SEROPHENE therapy.

8. When disorders such as diabetes, adrenal disease, or thyroid disease are identified during investigation, specific treatment should be undertaken and subfertility therapy reconsidered only after the underlying disorder has been adequately treated. SEROPHENE cannot be expected to be a substitute for specific therapy of these conditions.

CONTRAINDICATIONS

Pregnancy
SEROPHENE (clomiphene citrate) should not be administered during pregnancy since studies in rats and rabbits have shown clomiphene to be teratogenic (see “REPRODUCTION STUDIES”).

Studies in humans have not been done. However, there have been reports of congenital malformations and fetal death associated with clomiphene administration in humans, although a direct causal relationship has not been established. To prevent inadvertent SEROPHENE administration during early pregnancy, careful pelvic examination must be done prior to each course of therapy, the basal body temperature must be recorded throughout all treatment cycles, and the patient should be carefully observed to determine whether ovulation has occurred. If the basal body temperature following SEROPHENE is biphasic and is not followed by menses, the patient should be examined carefully for the presence of an ovarian cyst and should have a pregnancy test. The next course of therapy should be delayed until the possibility of pregnancy has been excluded.

Medical Problems
SEROPHENE should not be used when the following medical problems exist (reasons given where appropriate):

- Liver disease – SEROPHENE therapy is contraindicated in patients with active liver disease or history of hepatic function impairment
- Abnormal bleeding - SEROPHENE is contraindicated in patients with abnormal bleeding of undetermined origin. (Careful evaluation is recommended; neoplastic lesions should not be overlooked). SEROPHENE is not indicated for the management of menstrual disorders
- Fibroid tumours of the uterus
- Ovarian cyst - SEROPHENE should not be given in the presence of an ovarian cyst not due to polycystic ovarian syndrome, since further enlargement of the ovary may occur
- Mental depression
- Thrombophlebitis

WARNINGs

Multiple Births
The patient and her partner should be warned of the possibility of multiple births after treatment with SEROPHENE. This is the consequence of the stimulation of the ovarian function with the frequent production of several follicles. Among 1803 pregnancies on which the outcome was reported, 90% were single, and 10% were twins. Less than 1% of the reported deliveries resulted in triplets or more. Of these multiple pregnancies, 96-99% resulted in the births of live infants.

Visual Symptoms
Patients should be advised that blurring or other visual symptoms, dizziness or light-headedness may occasionally occur during therapy with SEROPHENE (clomiphene citrate).

Patients should be warned that visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting. The significance of these visual symptoms is not yet understood (see “ADVERSE REACTIONS”). If the patient has any visual symptoms, treatment should be discontinued and complete ophthalmologic evaluation carried out.

PRECAUTIONS

Diagnosis prior to SEROPHENE therapy:
Careful attention should be given to diagnosis in candidates for SEROPHENE (clomiphene citrate) therapy. Complete pelvic examination including cervical cytology is mandatory prior to treatment, and pelvic examination should be repeated before each subsequent course. SEROPHENE should not be given in the presence of an ovarian cyst, since further enlargement of the ovary may occur.

Patients in later reproductive life have a greater tendency to endometrial carcinoma as well as a higher incidence of anovulatory disorders. If abnormal bleeding is present, full diagnostic measures are mandatory.
Overstimulation of the ovary during SEROPHENE therapy:

In order to minimize the hazard associated with the occasional abnormal ovarian enlargement associated with SEROPHENE (clomiphene citrate) therapy (see “ADVERSE REACTIONS”), the lowest dose consistent with expectation of good results should be used. The patient should be advised of the possibility of ovarian cyst formation and should be instructed to return for repeat pelvic examination between 2 and 3 weeks after starting each course of treatment.

Some patients with polycystic ovarian syndrome who are unusually sensitive to gonadotropin may have an exaggerated response to usual doses of SEROPHENE.

It should be borne in mind that maximal enlargement of the ovary, whether physiologic or abnormal, does not occur until several days after discontinuation of the recommended dose of SEROPHENE. The patient who complains of pelvic pain after receiving SEROPHENE should be examined with care. If enlargement of the ovary occurs, additional SEROPHENE therapy should not be given until the ovaries have returned to pretreatment size, and the dosage or duration of the next course should be reduced. Experience has shown that the ovarian enlargement and cyst formation associated with SEROPHENE therapy regress spontaneously within a few days or weeks after discontinuing treatment. Unless surgical indication for laparotomy exists, such cystic enlargement should always be managed conservatively.

Diagnostic Interference
- Plasma desmosterol concentrations (only with long-term use, possibly indicating interference with cholesterol synthesis) and
- Plasma transcortin concentrations and
- Serum thyroxine concentrations and
- Sex hormone-binding globulin concentrations and
- Sulfochromophthalein (BSP) retention (indicating hepatotoxicity) and
- Thyroxine-binding globulin (TBG) concentrations (may be increased).

Carcinogenicity
Two cases of bilateral breast carcinoma in women treated with clomiphene have been reported.

Patient check-ups
The following procedures may be especially important in patient monitoring (other tests may be warranted in some patients, depending on condition):

Complete pelvic examination for evaluation of ovarian size (recommended prior to each course of treatment with clomiphene)
- Daily basal body temperature and
- Estrogen excretion determinations and
- Histological studies of luteal phase endometrium and
• Serum progesterone concentrations

Endometrial biopsy (recommended prior to initiation of clomiphene treatment in older patients to rule out the presence of endometrial carcinoma).

Liver function tests (recommended prior to initiation of therapy with clomiphene).

Ophthalmologic, including slit-lamp, examination (recommended if treatment with clomiphene is continued for more than 1 year).

ADVERSE REACTIONS

SEROPHENE, at recommended dosages, is generally well tolerated. Adverse reactions are usually mild and transient and most disappear promptly after treatment has been discontinued. Incidence and severity of adverse reactions tend to be related to dose and duration of treatment.

Adverse Events in Clinical Trials
The following frequency of adverse events have been recorded in 5836 patients treated with clomiphene citrate. Only events whose frequency was higher than 1% are reported below:

Body as a Whole:
Common: Abdominal-pelvic discomfort/distention/bloating (7.0%)

Central Nervous System disorders:
Common: Headache (1.3%)

Gastro-intestinal disorders:
Common: Nausea and vomiting (2.1%)

Reproductive system and breast disorders:
Very common: Ovarian enlargement (13.8%)
Common: Breast discomfort (2.0%), Abnormal uterine bleeding (intermenstrual spotting, menorrhagia) (1.3%)

Vascular disorders:
Very common: Vaso-motor flushes (10.6%)

Visual disorders:
Common: Visual symptoms (blurred vision, lights, floaters, waves, unspecified visual complaints, photophobia, diplopia, scotomata, phosphene) (1.6%)

Post-Market Adverse Drug Reactions
Among the adverse experiences reported spontaneously with SEROPHENE, the following are deemed to have a possible causal relationship with SEROPHENE:

**Endocrine disorders:** Monolateral exophthalmos

**Fetal and congenital anomalies:** Although isolated cases of congenital anomalies have been observed after treatment with SEROPHENE. SEROPHENE has not been shown to alter the incidence of congenital malformations observed in the offspring of women with fertility problems.

**Gastro-intestinal disorders:** Acute pancreatitis, nausea, vomiting, constipation, diarrhea

**Hepatic disorders:** Increase in transaminases, yellowing of eyes (hepatotoxicity)

**Investigations:** Sulfobromophthalein (BSP) retention of greater than 5%

**Metabolism and nutrition disorders:** Hypertriglyceridemia, weight gain

**Neoplasms:** Rare cases of ovarian cancer have been observed after drug treatment of infertility. Infertility is a primary risk factor for ovarian cancer; however, some epidemiology data suggest that prolonged use of SEROPHENE may increase the risk of ovarian tumor.

**Nervous disorders:** Dizziness or light-headedness, mental depression, nervousness, restlessness, sleeplessness or tiredness

**Renal and urinary disorders:** Increased urinary frequency or volume

**Reproductive system and breast disorders:** Endometriosis, heavier menses, ovarian enlargement or cysts, increased incidence of multiple pregnancies and possible premature deliveries, decrease in cervical mucous which may interfere with response

**Skin and subcutaneous tissue disorders:** Uticaria or allergic dermatitis; moderate, reversible hair loss

**Vascular disorders:** Thrombophlebitis

**Visual disorders:** Abnormal accommodation, blurred vision, photopsia, cataract, eye pain, macular edema, optic neuritis

**Birth Defects**

From 2,339 completed pregnancies associated with clomiphene citrate administration, 58 birth defects have been reported, for a cumulative rate of 2.5%. They have been reported in 4 conceptions in the abortion/stillbirth category, 14 of 353 infants from multiple
pregnancies, and 39 of 1,676 infants from single pregnancies. Three live-born infants failed to survive.

Reported defects were congenital heart lesions (8 infants), Down's syndrome (5 infants), club foot (4 infants), congenital gut lesions (4 infants), hypospadias (3 infants), microcephaly (2 infants), harelip and cleft palate (2 infants), congenital hip (2 infants), polydactyly (both twins), conjoined twins with teratomatous malformation, patent ductus arteriosus, amaurosis (blindness), arteriovenous fistula, inguinal hernia, umbilical hernia, syndactyly, pectus excavatum, myopathy, dermoid cyst of scalp, omphalocele, spina bifida occulta, ichthyosis, persistent lingual frenulum, and 7 infants with multiple somatic defects.

Eight of the entire group of 58 infants were born to 7 of 153 mothers who received a course of clomiphene citrate during the first 6 weeks after conception.

An interval of 4, 4, and 10 months respectively elapsed between the last clomiphene citrate therapy and conception in 3 mothers. In a fourth mother, conception occurred during a subsequent ovulation induced by gonadotropin therapy.

The cumulative rate of congenital abnormalities does not exceed that reported in the general population\(^2,30\).

**TREATMENT OF OVERDOSAGE**

For management of suspected drug overdose, contact your regional Poison Control Centre.

There is no known antidote, but gastric lavage should be performed.

**PATIENT CONSULTATION**

Consider advising the patient on the following:

Before using this medication:

- Possibility of multiple pregnancy
- See also PRECAUTIONS.

Proper use of this medication:

- Compliance with therapy; clarification of schedule; taking at the same time every day to aid in remembering each dose.

- Missed dose: Taking as soon as possible; doubling dose if not remembered until time of next dose; checking with physician if more than one dose missed.

Precautions while using this medication:
Importance of not taking medication while pregnant; importance of close monitoring by physician.

Importance of following physician's instructions for recording of temperature and timing of intercourse.

Caution when driving or doing jobs requiring alertness because of visual disturbances, dizziness, or lightheadedness.

Adverse reactions:

See ADVERSE REACTIONS.

GENERAL DOSING INFORMATION

Patients receiving clomiphene should be under supervision of a physician experienced in the treatment of gynecologic or endocrine disorders. Patients should be chosen for therapy with SEROPHENE (clomiphene citrate) only after careful diagnostic evaluation (see “INDICATIONS”).

The plan of therapy should be outlined in advance. Impediments to achieving the goal of therapy must be excluded or adequately treated before beginning SEROPHENE.

Patients who have been hypoestrogenic for prolonged periods may require pretreatment with estrogen to provide a more normal endometrium for ovum implantation. Estrogen therapy should be discontinued immediately before initiation of clomiphene citrate.

In some patients, a single injection of 5,000 to 10,000 USP units of human chorionic gonadotropin (hCG) is given 3 to 7 days after the last dose of clomiphene to stimulate the midcycle LH surge which results in ovulation.

Many patients will respond to 50 mg of SEROPHENE (clomiphene citrate) daily for 5 days (see “RECOMMENDED DOSAGE”). In the determination of a recommended starting dose schedule, efficacy must be balanced against potential adverse reactions. For example, the data available so far suggest that ovulation and pregnancy are slightly more attainable on 100 mg/day for 5 days than on 50 mg/day for 5 days. As the dosage is increased, however, ovarian overstimulation and other adverse reactions may be expected to increase. Furthermore, although the data does not yet establish a relationship between dosage and multiple births, it would seem reasonable on pharmacologic grounds that such a relationship does exist. For these reasons, it would seem prudent to begin the treatment of the usual patient with a lower dose, 50 mg daily for 5 days, and to increase the dose only in those patients who do not respond to the first course (see “RECOMMENDED DOSAGE”).
Patients with unusual sensitivity to pituitary gonadotropins (for example, those with polycystic ovarian syndrome) may require a lower dosage or shorter duration of clomiphene therapy. Use of clomiphene is not recommended in patients with ovarian cysts because further enlargement may occur. A patient's report of abdominal pain during clomiphene therapy indicates immediate pelvic examination. If ovarian enlargement or cyst formation has occurred, it is recommended that clomiphene therapy be withdrawn until the ovaries have returned to pretreatment size, usually within a few days or weeks. Dosage and duration of the next course of clomiphene should be reduced. If the patient receiving clomiphene experiences any visual disturbances, it is recommended that clomiphene therapy be withdrawn and a complete ophthalmologic examination performed. Ocular adverse reactions usually disappear within a few days or weeks after the last dose of clomiphene.

The majority of patients who are going to respond will respond to the first course of therapy, and 3 courses should constitute an adequate therapeutic trial. Treatment beyond this is not recommended in the patient who does not exhibit evidence of ovulation. If ovulatory menses does not occur after 3 to 4 cycles of clomiphene therapy at the maximum dose, or pregnancy after a treatment-free interval of 3 to 6 months, the diagnosis should be reevaluated.

**Pregnancy**

In most patients, ovulation appears to occur from 6 to 12 days after completion of therapy. For regularity of cyclic ovulatory response, it is also important that each course of SEROPHENE be started on or about the fifth cycle day, once ovulation has been established. The importance of properly timed coitus cannot be over-emphasized. Conception should be attempted by having intercourse every other day, starting within 48 hours before ovulation.

If a cycle of SEROPHENE is followed by a biphasic course of basal body temperature and menses do not ensue, the next cycle of SEROPHENE should be delayed until it is confirmed that the patient is not pregnant.

In common with other therapeutic modalities, SEROPHENE therapy follows the rule of diminishing returns, such that likelihood of conception diminishes with each succeeding course of therapy. If pregnancy has not been achieved after 3 ovulatory responses to SEROPHENE, further treatment is not recommended. Patients should be advised of the possibility of multiple pregnancy and its potential hazards if conception occurs during a cycle in which SEROPHENE is given.

**RECOMMENDED DOSAGE**

SEROPHENE (clomiphene citrate) tablets.

Usual adult dose: Oral, 50 mg (1 tablet) a day for five days, starting on the fifth day of the menstrual cycle, if bleeding occurs or at any time in the patient who has had no recent
uterine bleeding. If ovulation without conception occurs, this cycle is repeated until conception or for three or four cycles. When ovulation occurs at the regimen of 50 mg daily for 5 days, there is no advantage to increasing the dose in subsequent cycles of treatment. If ovulation does not occur, the dose is increased to 100 mg a day for five days (starting as early as 30 days after the previous course), repeated if ovulation without conception occurs.

The maximum daily dose of clomiphene is 100 mg for 5 consecutive days for the maximum of 6 cycles.

Note: The majority of patients who are going to respond will respond to the first course of therapy, and 3 courses should constitute an adequate therapeutic trial. If ovulatory menses do not occur after 3 cycles of clomiphene therapy at the maximum dose, or pregnancy after a treatment-free interval of 3 to 6 months, the diagnosis should be reevaluated. Treatment beyond this is not recommended in the patient who does not exhibit evidence of ovulation.

**AVAILABILITY**

SEROPHENE (clomiphene citrate) is available as 50 mg scored white tablets, packaged in bottles of 50 and blister packs of 10.

**Storage**

Preserve in well-closed containers, protected from light, between 15-30°C.
CHEMISTRY

**Proper name:** Clomiphene Citrate

**Structural formula:**

![Chemical Structure of Clomiphene Citrate](image)

**Molecular Formula:** C_{26}H_{28}ClNO.C_{6}H_{8}O_{7}

**Molecular Weight:** 598.09

Chemical Name: 2-[p-(2-chloro-1,2-diphenylvinyl) phenoxy] triethylamine dihydrogen citrate.

**Description:** Clomiphene citrate is white to pale yellow, essentially odourless. It is slightly soluble in water and chloroform, freely soluble in methanol, sparingly soluble in alcohol, insoluble in ether.

PHARMACOLOGY

Clomiphene citrate is absorbed from the gastrointestinal tract and slowly excreted through the liver into the bile. The biological half life is reported to be 5 days. Enterohepatic recirculation takes place.

SEROPHENE (clomiphene citrate) was found to inhibit endogenous pituitary gonadotropetric activity in rats based on organ weight indices, but did not block superovulation produced in immature female rats by pregnant mare's serum and chorionic gonadotropin. It also produced a reversible anti-fertility effect in both male and female rats. In immature female mice, SEROPHENE acted both as a weak estrogen, judged by
its uterotrophic effect, and as antiestrogen because of its antagonism to the uterotrophic effect of estradiol monobenzoate. SEROPHENE had no progestational, androgenic, or anti-androgenic effects and appeared not to interfere with pituitary-adrenal or pituitary-thyroid function. In rats and dogs, a dose-dependent decrease in plasma cholesterol and total sterols, and an increase in desmosterol were observed after higher doses.

Studies with C-14 labelled clomiphene citrate in rats indicate that it is readily absorbed after oral administration and is excreted principally in the feces. Rats with biliary fistulas excreted the C-14 label in the bile, and enterohepatic recirculation was demonstrated. Low levels of C-14 were observed in pituitary and testis of both rats and monkeys, whereas the ovary had levels close to the median value of tissues examined.

**BIOAVAILABILITY**

In a 3-way cross-over study in healthy fasting female subjects, comparison of the plasma concentration versus time curves by repeated measures, ANOVA showed that there is no significant difference among clomiphene citrate tablets manufactured by Merrell Dow Pharmaceutical Inc., U.S.A.; Merrell Canada; and Serono Labs Inc. (SEROPHENE tablets) with regard to the blood levels they produce. Comparison of the pharmacokinetic parameters $AUC_{(0-24h)}$, $AUC_{(0-336 h)}$, $T_{\text{max}}$, and $C_{\text{max}}$ by ANOVA testing showed that there were no significant effects due to treatment. This, it can be concluded that the products are equivalent with regard to the rate and extent of absorption.

**TOXICOLOGY**

High levels of C-14 were found in the ocular tissue after intravenous administration in rats, dogs, and monkeys. In rats, the acute LD50 was 5750 mg/kg on oral administration and 530 mg/kg I.P. The acute LD50 in mice was 1700 mg/kg orally, 390 mg/kg I.P.; and 86 mg/kg I.V. Convulsions occurred in dogs after infusion of 40 to 62 mg/kg and the animals died of respiratory failure at 112 and 121 mg/kg. In chronic toxicity studies, clomiphene citrate was administered at various dose levels to rats and dogs for as long as 53 weeks. Some decrease in growth rate and food consumption was observed at all dose levels in rats but not in dogs. No significant hematologic changes were observed, and in the dog, serum transaminase, alkaline phosphatase, bilirubin, glucose, blood urea nitrogen levels, and urinalysis were within normal limits. Changes in the reproductive system compatible with inhibition of gonadotropin were observed in both species.

Thinning of fur occurred in rats receiving 5 to 40 mg/kg/day for 53 weeks, with incidence related to dose and duration of therapy. Subcapsular cataracts occurred in 4 of 29 rats (but not in dogs) receiving 40 mg/kg/day, which were sacrificed at 53 weeks; in one of these animals, opacities had first appeared at 31 weeks. No cataracts were observed in rats receiving 15 mg/kg and 5 mg/kg for 53 weeks. At the end of 53 weeks, one dog exhibited an eye derangement in the form of a granular, dot-like opacity.

**REPRODUCTION STUDIES**

After oral administration of clomiphene citrate to pregnant rats during the interval of organogenesis in doses of 1.6 to 200 mg/kg/day, malformations were observed in the...
pups from one of five liters in the group receiving 8 mg/kg/day. Higher oral doses (40-200 mg/kg/day) inhibited fetal development and only one litter (normal) was born. Subcutaneous administration of clomiphene citrate to pregnant rats on one day (12th) during the period of organogenesis resulted in a dose-dependent increase in the incidence of malformations in doses of 1.0 to 1,000 mg/kg. In rabbits, deformed fetuses were seen following oral doses of 20 and 40 mg/kg/day from the eighth through the fifteenth day of a 32-day gestation. None was seen after the oral dose of 8 mg/kg/day.
REFERENCES

34. Bioavailability report on file, Serono Canada Inc.